Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3651-3660 Newer>

Managed Care April 2007	The Formulary Files Eighty percent of hospitalized kids prescribed off-label drugs.
The Motley Fool April 27, 2007 Brian Lawler	PDL Gets the Go-Ahead Signal The biopharma moves its lead compound into phase 3 testing. Investors, take note.
The Motley Fool April 26, 2007 Brian Lawler	Brazil's Boneheaded Drug Move Brazil already receives a steep discount on the price that Merck charges it for its HIV compounds. Nevertheless, it wants still lower prices to help reduce the government's costs associated with supplying drugs to those living with HIV/AIDS.
The Motley Fool April 26, 2007 Mike Havrilla	Dendreon Is Worth a Shot Provenge might be approved, which means investors might be rewarded. However, the massive short interest also highlights the tremendous risk in Dendreon.
The Motley Fool April 26, 2007 Brian Lawler	Lilly Tries to Make Dogs Happy Eli Lilly begins marketing a new drug that treats "separation anxiety" in dogs, which supposedly can occur when Fido is left alone apart from his owner for even a short period of time. Investors, take note.
The Motley Fool April 25, 2007 Rich Duprey	BSD Medical Is Ready to Overheat Its hyperthermia treatment may hold promise, but the health-care firm looks like it's getting ready to burn investors.
Chemistry World April 24, 2007 Victoria Gill	AstraZeneca Scoops up $15.6 Billion Vaccine Business AstraZeneca has joined the race to scoop up acquisition opportunities in the biologics sector with a $15.6 billion deal to buy U.S. vaccines and biotechnology company MedImmune.
The Motley Fool April 24, 2007 Tim Beyers	Scrushy Escapes the SEC First, former HealthSouth CEO-cum-televangelist Richard Scrushy beat the rap. Then he beat the SEC. Letting him off the hook this easily sets back corporate governance at least as far as the conviction of Nacchio advanced it.
The Motley Fool April 24, 2007 Brian Lawler	AtheroGenics Loses a Partner The specialty drug maker's drug-development partner bails. Waiting around for years on more clinical trial results for a drug with such unproven efficacy is not something that is a recipe for success with specialty pharma stock investing.
The Motley Fool April 24, 2007 Brian Lawler	MedImmune Not Immune to Takeovers MedImmune shops itself to AstraZeneca. MedImmune investors appear to be getting a pretty sweet deal.
<Older 3651-3660 Newer> Return to current articles.